27.04

1.05% 0.28

After Hours: 27.03 -0.010 -0.04%

Harmony Biosciences Holdings Inc (HRMY)

Overview News Price History Option Chain Financials Why HRMY Down? Discussions Forecast

Harmony Biosciences Holdings Inc stock is traded at $27.04, with a volume of 1.68M. It is up +1.05% in the last 24 hours and down -27.74% over the past month. Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Previous Close:

$26.76

Open:

$26.71

24h Volume:

1.68M

Relative Volume:

2.38

Market Cap:

$1.56B

Revenue:

$681.88M

Net Income/Loss:

$122.63M

P/E Ratio:

12.82

EPS:

2.11

Net Cash Flow:

$220.18M

1W Performance:

-17.13%

1M Performance:

-27.74%

6M Performance:

-18.04%

1Y Performance:

-27.49%

1-Day Range:

$26.35

$27.06

1-Week Range:

$26.35

$33.21

52-Week Range:

$26.35

$41.61

Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile

Name

Harmony Biosciences Holdings Inc

Sector

Healthcare (1143)

Industry

Biotechnology (642)

Phone

(484) 539-9800

Address

630 W GERMANTOWN PIKE, PLYMOUTH MEETING

Employee

268

Twitter

Next Earnings Date

2024-10-29

Latest SEC Filings

HRMY's Discussions on Twitter

Compare HRMY with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
HRMY Harmony Biosciences Holdings Inc	27.04	1.54B	681.88M	122.63M	220.18M	2.11
VRTX Vertex Pharmaceuticals Inc	381.87	96.56B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	449.58	60.08B	2.46B	-319.09M	-52.09M	-2.47
REGN Regeneron Pharmaceuticals Inc	555.51	61.15B	14.21B	4.46B	3.56B	39.68
ARGX Argen X Se Adr	711.09	44.66B	3.06B	1.28B	447.35M	21.30
ONC Beone Medicines Ltd Adr	328.71	36.23B	3.81B	-644.79M	-669.77M	-6.24

Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-21-25	Initiated	Truist	Buy
Jul-10-25	Resumed	Goldman	Neutral
Jun-02-25	Resumed	Oppenheimer	Outperform
Feb-11-25	Initiated	Deutsche Bank	Buy
Dec-17-24	Initiated	H.C. Wainwright	Buy
Oct-10-24	Resumed	Raymond James	Outperform
Sep-10-24	Initiated	UBS	Buy
Jun-21-24	Initiated	Citigroup	Buy
Jan-02-24	Downgrade	BofA Securities	Neutral → Underperform
Sep-25-23	Downgrade	Goldman	Neutral → Sell
Sep-07-23	Initiated	Berenberg	Buy
Apr-20-23	Initiated	BofA Securities	Neutral
Oct-14-22	Upgrade	Janney	Neutral → Buy
Oct-14-22	Upgrade	Jefferies	Hold → Buy
Aug-03-22	Downgrade	Jefferies	Buy → Hold
Jul-13-22	Downgrade	Goldman	Buy → Neutral
Jul-07-22	Initiated	Mizuho	Buy
Apr-14-22	Initiated	Cantor Fitzgerald	Overweight
Dec-01-21	Initiated	Oppenheimer	Outperform
Nov-04-21	Initiated	Raymond James	Outperform
Sep-23-21	Initiated	Needham	Buy
Mar-29-21	Upgrade	Goldman	Neutral → Buy
Sep-14-20	Initiated	Goldman	Neutral
Sep-14-20	Initiated	Jefferies	Buy
Sep-14-20	Initiated	Piper Sandler	Overweight

View All

Harmony Biosciences Holdings Inc Stock (HRMY) Latest News

02:36 AM

Harmony Biosciences: Cannabinoid Fragile X Fail Merits Rating Downgrade (NASDAQ:HRMY) - Seeking Alpha

02:36 AM

02:14 AM

Harmony Biosciences stock price target lowered to $55 at H.C. Wainwright - Investing.com India

02:14 AM

01:04 AM

Mizuho Issues Pessimistic Forecast for Harmony Biosciences (NASDAQ:HRMY) Stock Price - MarketBeat

01:04 AM

01:03 AM

Mizuho Lowers Price Target for Harmony Biosciences (HRMY) to $35 - GuruFocus

01:03 AM

11:27 AM

HRMY Stock Down as Fragile X Syndrome Study Fails to Meet Goal - The Globe and Mail

11:27 AM

11:26 AM

Harmony Biosciences' ZYN002 Failure Closes Off Key Revenue Diversification Path, Deutsche Bank Says - MarketScreener

11:26 AM

10:52 AM

Harmony Biosciences (NASDAQ:HRMY) Reaches New 12-Month Low on Analyst Downgrade - MarketBeat

10:52 AM

10:34 AM

Harmony Biosciences (HRMY): Deutsche Bank Adjusts Price Target | - GuruFocus

10:34 AM

09:42 AM

Deutsche Bank Aktiengesellschaft Cuts Harmony Biosciences (NASDAQ:HRMY) Price Target to $36.00 - MarketBeat

09:42 AM

09:36 AM

HRMY: HC Wainwright & Co. Lowers Price Target to $55, Maintains Buy Rating | HRMY Stock News - GuruFocus

09:36 AM

08:55 AM

Harmony Biosciences (NASDAQ:HRMY) Price Target Lowered to $55.00 at HC Wainwright - MarketBeat

08:55 AM

07:20 AM

Ruffer LLP Takes $2.72 Million Position in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat

07:20 AM

07:17 AM

Mizuho Cuts Price Target on Harmony Biosciences to $35 From $50, Keeps Outperform Rating - MarketScreener

07:17 AM

07:00 AM

Mizuho lowers Harmony Biosciences stock price target to $35 after trial setback - Investing.com UK

07:00 AM

06:55 AM